Sorafenib: Atypical cutaneous side effects [12]

European Journal of Dermatology

Volumn 17, Issue 6, 2007, Pages 549-550

  Richetta, Antonio Giovanni ^a   Maiani, Elisa ^a   Carboni, Valentina ^a   Carlomagno, Valentina ^a   Cimillo, Manuella ^a   Mattozzi, Carlo ^a   Calvieri, Stefano ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; D DIMER; FIBRINOGEN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NITROGEN; PLATELET DERIVED GROWTH FACTOR B; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; UREA; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AGED; BLEEDING; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DISEASE DURATION; DRUG INHIBITION; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; ERYTHEMA; FACE ERYTHEMA; FATIGUE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LABORATORY TEST; LEG EDEMA; LETTER; LUNG EDEMA; MALE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; RASH; RECURRENT DISEASE; THORAX RADIOGRAPHY;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DRUG ERUPTIONS; HUMANS; MALE; MAP KINASE KINASE KINASES; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN DISEASES, VESICULOBULLOUS;

EID: 36749021640     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar®, a 22 Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods Enzymol 2005; 407: 597-612.
2. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006;1 8 (6): 615-21.
3. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6(7): 491-500.
4. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 2006; 20(5 Suppl 2): 26-34.
5. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rush associated with treatment outcome? Eur J Cancer 2006; 42: 548-56.
6. Chung NM, Gutierrez M, Turner ML. Leukocytoclastic Vasculitis Masquerading as Hand-foot Syndrome in a Patient Treated With Sorafenib. Arch Dermatol 2006; 142: 1510-1.